ClinicalTrials HQ

A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

Active, not recruiting · NCT06957080 · Registry updated 2026-08-20
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DMEDiabetic Macular Edema (DME)Active, not recruitingPhase 2 / Phase 32026-08-20NCT06957080

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
EyeBiotech Ltd.5

164 results · Page 1 of 7

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Abilene, TXAbileneUnited States2
Aiken, SCAikenUnited States1
Albuquerque, New MexicoAlbuquerqueUnited States1
Amagasaki, JapanAmagasakiJapan1
Amarillo, TXAmarilloUnited States2
Aparecida de Goiania, BrazilAparecida de GoiâniaBrazil1
Aparecida De Goiania, BrazilAparecida de GoiâniaBrazil1
Arecibo, PRAreciboPuerto Rico1
Arlington, TXArlingtonUnited States2
Asahikawa, JapanAsahikawaJapan1
Asheville, NCAshevilleUnited States2
Assis, BrazilAssisBrazil1
Austin, TXAustinUnited States3
Bakersfield, CABakersfieldUnited States2
Baltimore, MarylandBaltimoreUnited States1
Barranquilla, ColombiaBarranquillaColombia1
Beaufort, NCBeaufortUnited States1
Beaufort, SCBeaufortUnited States2
Bellaire, TXBellaireUnited States4
Bellevue, WashingtonBellevueUnited States1
Belo Horizonte, BrazilBelo HorizonteBrazil1
Bethlehem, PABethlehemUnited States2
Bloomfield, NJBloomfieldUnited States3
Bluffton, NCBlufftonUnited States1
Blumenau, BrazilBlumenauBrazil1